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A Pilot Genome-Wide Analysis Study 
Identifies Loci Associated With Response 
to Obeticholic Acid in Patients With 
NASH
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A significantly higher proportion of patients with nonalcoholic steatohepatitis (NASH) who received obeticholic acid 
(OCA) had histological improvement relative to placebo in the FLINT (farnesoid X nuclear receptor ligand obet-
icholic acid for noncirrhotic, NASH treatment) trial. However, genetic predictors of response to OCA are unknown. 
We conducted a genome-wide association study (GWAS) in FLINT participants to identify variants associated with 
NASH resolution and fibrosis improvement. Genotyping was performed using the Omni2.5 content GWAS chip. To 
avoid false positives introduced by population stratification, we focused our GWAS on white participants. Six regions 
on chromosomes 1, 4, 6, 7, 15, and 17 had multiple single nucleotide polymorphisms (SNPs) with suggestive associa-
tion (P  <  1  × 10−4) with NASH resolution. A sentinel SNP, rs75508464, near CELA3B on chromosome 1 was associ-
ated with NASH resolution, improvement in the nonalcoholic fatty liver disease activity score, portal inflammation, 
and fibrosis. Among individuals carrying this allele, 83% achieved NASH resolution with OCA compared with only 
33% with placebo. Eight regions on chromosomes 1, 2, 3, 11, 13, and 18 had multiple SNPs associated with fibrosis 
improvement; of these, rs12130403 near TDRD10 on chromosome 1 was also associated with improvement in NASH 
and portal inflammation, and rs4073431 near ANO3 on chromosome 11 was associated with NASH resolution and 
improvement in steatosis. Multiple SNPs on chromosome 11 had suggestive association with pruritus, with rs1379650 
near ANO5 being the top SNP. Conclusion: We identified several variants that may be associated with histological 
improvement and pruritus in individuals with NASH receiving OCA. The rs75508464 variant near CELA3B may have 
the most significant effect on NASH resolution in those receiving OCA. (Hepatology Communications 2019;3:1571-1584).
Nonalcoholic steatohepatitis (NASH) is a subphenotype of nonalcoholic fatty liver disease (NAFLD) that is associated with 
hepatic inflammation, cell injury, and fibrosis.(1) 
NASH is a progressive condition that can lead to 
cirrhosis, liver failure, and liver cancer. Thus, there 
is great interest in developing novel therapies for 
NASH in both adults and children.(2) We published 
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the results of a multicenter, randomized, placebo- 
controlled trial of farnesoid X nuclear receptor 
ligand obeticholic acid for noncirrhotic, NASH 
treatment (FLINT).(3) This study showed that obe-
ticholic acid (OCA) administered daily for 72 weeks 
was associated with significant improvement in ste-
atosis, necroinflammation, and fibrosis in patients 
with NASH. However, only a subgroup of patients 
receiving OCA achieved favorable changes in liver 
histology, and similarly adverse events such as pru-
ritus were observed only in a subgroup of patients 
receiving OCA.
Pharmacogenomics is the study of the role of 
genetic variants in the response to a particular med-
ication and development of adverse events with such 
medication.(4) Previous studies in other liver diseases 
have shown that pharmacogenomics may be helpful 
in predicting treatment response or side effects to 
medications. Genetic variants in the IL28 gene were 
highly predictive of response to interferon therapy in 
patients with chronic hepatitis C.(5) Variations in the 
HLA region are a well-known risk factor for liver 
injury due to antibacterial agents such as flucloxacillin, 
amoxicillin-clavulanate, or minocycline.(6-9) However, 
pharmacogenomics research within the NAFLD area 
is somewhat limited. One study showed that genetic 
variation in cytochrome P450 4F2 was not a signifi-
cant predictor of response to vitamin E in nondiabetic 
patients with biopsy-proven NASH.(10) More recently, 
genetic variation in haptoglobin was found to be sig-
nificantly associated with histological response to 
vitamin E.(11) Studies showed the PNPLA3 148 M/M 
allele to be associated with poor response to omega-3 
polyunsaturated fatty acids.(12,13) Another recent study 
showed that variants in PNPLA3 and TM6SF2 mod-
ify the risk for hepatic steatosis caused by a novel 
glucagon receptor antagonist, LY2409021, in patients 
with type 2 diabetes.(14)
Recently, the clinical and laboratory factors asso-
ciated with histological response to OCA in FLINT 
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have been reported.(15) These include treatment with 
OCA, baseline NAFLD activity score (NAS)  >  5, 
baseline triglyceride level ≤154 mg/dL, baseline inter-
national normalized ratio ≤1, baseline aspartate ami-
notransferase level ≤49 U/L, and a decrease in alanine 
aminotransferase (ALT) level at week 24 by 17 U/L or 
more. Although we have previously identified several 
genetic variants associated with histological features 
of NAFLD,(16) the genetic variants associated with 
NASH histological response to OCA are unknown.
We performed a GWAS of participants in the 
FLINT trial to identify genetic variants associated 
with histological improvement, specifically with 
NASH resolution and fibrosis improvement. As a sec-
ondary objective, we also conducted a GWAS to iden-
tify genetic variants associated with the development 
of pruritus among study participants.
Materials and Methods
paRtiCipants
The details of the FLINT study have been pub-
lished previously.(3) Briefly, FLINT was a random-
ized, placebo-controlled clinical trial that enrolled 283 
participants with biopsy-proven noncirrhotic NASH. 
Almost half of the study participants had type 2 dia-
betes. Participants were randomized to receive OCA 
25 mg orally daily or matching placebo for 72 weeks. 
Due to interim review of the study, only 200 par-
ticipants underwent baseline and end-of-treatment 
(week 72) liver biopsies. We genotyped 244 patients 
who participated in FLINT with available DNA, of 
whom 198 (81%) were white.
assessment oF liVeR 
Histology
The primary endpoint of FLINT was improve-
ment in NAFLD histology defined as a reduction 
of NAS ≥ 2 points without worsening fibrosis. Liver 
histology was blindly and centrally assessed by the 
NASH Clinical Research Network (NASH CRN) 
Pathology Committee. Evaluation and scoring of 
baseline and end-of-treatment liver biopsies were 
done according the NASH CRN system.(17) NASH 
resolution was defined as diagnostic classification of 
either not NAFLD, or NAFLD but not NASH, on 
week 72 biopsy. Fibrosis was assessed on a scale of 0-4, 
and fibrosis improvement was defined as a decrease in 
fibrosis stage by at least one stage.
genotyping
DNA was isolated from whole blood using stan-
dard procedures and transferred to the genotyping 
laboratory at the Los Angeles Biomedical Research 
Institute. Genotyping was performed using the 
Omni2.5 content GWAS chip. Genotypes were 
named using Illumina software (GenomeStudio 2.0). 
Allele naming included an extensive review of cluster 
plots, particularly for the exome content. Participants 
were removed for failed genotyping, unresolvable gen-
der discrepancies, being outliers by principal com-
ponent analyses, and by relatedness with ?̂? >0.2. 
Successful genotyping rates were >98% per subject 
and >98% per SNP. The 198 white participants with 
2,051,521 SNPs were further examined for quality 
control (QC) (Supporting Table S1). Cryptic relative 
checking found one pair of monozygotic twins, so one 
of them was randomly removed. Additional SNP-
level QC removed 613 SNPs due to missing rate >5% 
and another 32,941 SNPs due to Hardy-Weinberg 
Equilibrium <10−6. In total, 197 white samples with 
2,017,967 SNPs remained in the analysis data set.
pRinCipal Component 
analysis
To investigate potential population substructures in 
the sample, we carried out principal component anal-
ysis (PCA) using the GWAS data and the program 
smartPCA.(18,19) SNPs were filtered by minor allele fre-
quency (MAF)  <  0.05 and further pruned by linkage 
disequilibrium of 0.3, leaving 68,381 SNPs in the PCA. 
We found some modest population substructure in the 
study sample, and a significant percentage of the vari-
ance can be explained by the top three principal compo-
nent (PCs). Hence, the top three PCs were included in 
the GWAS analysis (Supporting Fig. S1A,B).
imputation
The genotype data were imputed to the Haplotype 
Reference Consortium population. Among the 
2,017,967 SNPs that passed QC, 1,919,289 passed the 
pre-imputation QC, which removed SNPs not in the 
reference panel, all A/T G/C SNPs with MAF > 40% 
in the reference data set, and all SNPs with an AF 
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difference >0.2 between the reference and data set fre-
quency file. In total, 197 samples with 1,906,129 SNPs 
on autosomes were then submitted to the Michigan 
Imputation Server. The server removed 50 SNPs 
due to invalid alleles, so 1,906,079 genotyped SNPs 
passed through and 37,225,499 SNPs were imputed. 
In total, there were 39,131,578 SNPs after imputa-
tion, with 5,417,859 SNPs having MAF  >  0.05 and 
the rest 33,713,719 having MAF ≤ 0.05.
genome-WiDe assoCiation 
analysis
Given most of the participants were white (81%), 
we focused our GWAS study on white participants 
only to avoid false positives introduced by population 
stratification. Common variant (MAF > 0.05) GWAS 
was then carried out for NASH resolution, a binary 
trait with 1 indicating NASH resolution and 0 indi-
cating lack of NASH resolution. As NASH resolution 
is a binary trait, we used a logistic model as follows:
where yi denotes the resolution status for the ith sub-
ject; Xi =
(
Xi1,Xi2,… ,Xim
) denotes the m covariates 
(e.g,. age, gender, baseline body mass index [BMI], 
percentage change in BMI, and top principal compo-
nents of genetic variation); and Gi =
(
Gi1,Gi2,… ,Gip
) 
denotes the genotypes for the p variants.
First, only the top three PCs were included as 
covariates:
Then, we included age and gender together with 
three PCs as covariates:
Next, we included baseline BMI together with 
three PCs, age, and gender as covariates:
Finally, because participants on OCA experienced 
an average weight loss of 2.3 kg versus none in those 
on placebo (P = 0.008), we included percentage change 
in BMI with all covariates in model 3:
The analysis was run by the Efficient and Parall-
elizable Association Container Toolbox (EPACTS) pro-
gram at http://genome.sph.umich.edu/wiki/EPACTS, 
first on all 197 FLINT white participants whose sam-
ples passed QC, then on the OCA-treated group (106 
samples), and finally on the placebo-treated group (91 
samples). Of those, 141 white participants (76 in the 
OCA group and 65 in the placebo group) had paired 
liver biopsies at baseline and at end of treatment and 
were included for genotype-histological response asso-
ciation analyses, whereas the pruritus GWAS was 
carried out in 197 white participants. Common vari-
ant (MAF  >  0.05) GWAS was also carried out for 
fibrosis improvement, a binary trait with 1 indicating 
fibrosis improvement and 0 indicating lack of fibrosis 
improvement. The Wald test was applied to test the 
true value of the parameter based on the sample esti-
mate. Based on the relatively small sample size, a P 
value of less than 10−4 was used to define top SNPs for 
further analysis. Additional analyses were conducted in 
those chromosomal regions where more than one SNP 
met the criterion for evaluation.
We used two criteria to select the SNPs and genetic 
regions for follow-up. First, we focus on SNPs with 
greatest significance (smallest P value) and identified 
the genes to which the SNPs belonged. If the SNP 
was not rare (MAF  >  0.05) and it is genotyped or 
imputed with high imputation quality, it is highly 
possible that the association is “real.”
Second, we focused on regions when having mul-
tiple SNPs with suggestive association (P < 1 × 10−4) 
within the same region. It is quite possible that 
SNPs within the same region represent the same 
genes that are likely to be significantly associated 
with histological resolution of NASH. Moreover, 
regions with multiple hits are more likely to have 
“real” association than single SNPs of the same 
significance.
logitP
(
yi =1
)
=훼0+훼
�Xi+훽
�Gi ,
Model 1: logitP
(
yi =1
)
= 훼0+훼1PC1i+훼2PC2i
+훼3PC3i+훽
�Gi .
Model 2: logitP
(
yi =1
)
= 훼0+훼1PC1i+훼2PC2i
+훼3PC3i+훼4agei
+훼5genderi+훽
�Gi .
Model 3: logitP
(
yi =1
)
= 훼0+훼1PC1i+훼2PC2i
+훼3PC3i+훼4agei+훼5genderi
+훼6BMI_bi+훽
�Gi .
Model 4: logitP
(
yi =1
)
= 훼0+훼1PC1i+훼2PC2i
+훼3PC3i+훼4agei
+훼5genderi+훼6BMI_bi
+훼7%change_BMIi+훽
�Gi .
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Results
Flint tRial
The results of FLINT have been previously pub-
lished.(3) Briefly, the study primary outcome, his-
tological improvement as indicated by reduction 
of NAS  ≥  2 points without worsening fibrosis, was 
observed in 45% of participants on OCA versus 
21% of those on placebo (P  =  0.0002). Resolution 
of definite NASH was achieved in 22% of patients 
on OCA versus 13% of those on placebo (P = 0.08). 
More patients on OCA versus placebo had significant 
improvement in fibrosis (35% versus 19%, P = 0.004), 
steatosis (61% versus 38%, P = 0.001), lobular inflam-
mation (53% versus 35%, P = 0.006), and hepatocyte 
ballooning (46% versus 31%, P  =  0.03). Pruritus was 
more commonly reported in patients on OCA versus 
placebo (23% versus 6%).
genome-WiDe assoCiation 
analysis FoR nasH 
Resolution
Among the 141 white participants who were ana-
lyzed, NASH resolution was observed in 22.3% 
(17 of 76) in the OCA group versus 12.3% (8 of 65) 
in the placebo group. These rates are very similar to 
that observed in each group in the entire FLINT study. 
Genome-wide association results are summarized in 
Manhattan plot and quantile-quantile (Q-Q) plots 
(Fig. 1). There were 120 SNPs that have suggestive asso-
ciation (P value < 1 × 10−4 ) for the binary trait NASH 
resolution in the entire FLINT white group. These sug-
gestive SNPs were distributed over 28 chromosomal loci 
on 16 different chromosomes. After adjusting for the 
top three PCAs plus age and gender (model 2), adding 
baseline BMI (model 3), and percentage change in BMI 
from baseline (model 4), the overall findings of associated 
chromosomal regions and sentinel SNPs were unchanged 
(Supporting Table S2). We therefore chose the first anal-
ysis model, which has the largest sample size.
CHRomosomal Regions anD 
snps assoCiateD WitH nasH 
Resolution
Six chromosomal regions had multiple SNPs with 
suggestive association on chromosomes (chr) 1, 4, 6, 
7, 15, and 17 (Supporting Fig. S2). Genes nearest to 
the sentinel SNPs include CELA3B (chr1), MAPK10 
(chr4), FYN (chr6), CREB3L2 (chr7), TMCO5A 
(chr15), and RPTOR (chr17).
Next we assessed the interacting effects of each of 
the identified sentinel SNPs in these loci with that of 
treatment received, on NASH resolution. By compar-
ing the effect in the OCA group versus placebo group, 
each sentinel SNP can have either a SNP effect only, 
or a SNP and treatment interaction effect (Fig. 2).
Of the 28 identified sentinel SNPs, 15 demon-
strated a SNP-only effect, whereas 13 had a SNP and 
treatment interaction effect in model 1 (Table 1). The 
data are most supportive for the six regions with mul-
tiple associated SNPs. The effects of the top SNPs in 
these six regions on NASH resolution are highlighted 
in the genotype bar plots in Fig. 3.
We then assessed the effects of these six sentinel 
SNPs associated with NASH resolution on other 
NASH histological phenotypes, ALT, and pruritus 
(Table 2). Although SNPs in chromosomes 7, 15, and 
17 were also associated with improvement in steatosis, 
the chromosome 1 sentinel SNP (rs75508464) near 
CELA3B was also associated with improvement in 
NAS, fibrosis, and portal inflammation. The associ-
ation with improvement in fibrosis was still observed 
when the analysis was restricted to the OCA-treated 
group. None of these sentinel SNPs was associated 
with ALT or development of pruritus.
genome-WiDe assoCiation 
analysis FoR FiBRosis 
impRoVement
Among the 141 white participants who were ana-
lyzed, fibrosis improvement was observed in 35.5% 
(27 of 76) in the OCA group versus 16.9% (11 of 
65) in the placebo group. These rates are very similar 
to that observed in each group in the entire FLINT 
study. There were 252 SNPs with suggestive associa-
tion (P value < 1 × 10−4) in model 1 with the binary 
trait fibrosis improvement (yes or no) in the entire 
FLINT white group. These suggestive SNPs were 
distributed over 26 chromosomal loci on 16 different 
chromosomes (Fig. 4).
After adjusting for the top three PCs plus age and 
gender (model 2), adding baseline BMI (model 3) and 
percentage change in BMI from baseline (model 4), 
the sentinel SNPs and chromosomal regions associated 
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Fig. 1. Manhattan and Q-Q plots for NASH resolution in the entire cohort (A), in the OCA-treated group (B), and in the placebo-
treated group (C).
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with fibrosis improvement remained at the same level 
of significance (Supporting Table S3).
CHRomosomal Regions anD 
snps assoCiateD WitH FiBRosis 
impRoVement
Of the 26 chromosomal regions that had SNPs 
with suggestive associations with fibrosis improve-
ment, we focused on the eight regions with multiple 
associated SNPs on chromosomes 1, 2, 3, 11, 13, and 
18 (Supporting Fig. S3). Genes nearest to the senti-
nel SNPs include TDRD10 (chr1), DYNC1I2 (chr2), 
TPRG1 (chr1), ANO3 (chr11), LINC00348 (chr13), 
and CDH2 (chr18).
Supporting Table S4 summarizes the top SNPs that 
showed suggestive evidence of association with fibrosis 
improvement. Four SNPs had primarily a SNP-only 
effect on fibrosis improvement, while another four 
SNPs appeared to affect fibrosis improvement through 
interaction with treatment effect (Supporting Fig. S4).
We then assessed the effects of these SNPs associ-
ated with fibrosis improvement on other NASH histo-
logical phenotypes, ALT, and pruritus (Table 3). Several 
sentinel SNPs were also nominally associated with 
NASH resolution or improvement, but rs12130403 
Fig. 2. Illustrative examples of interacting sentinel SNP and 
treatment effects on NASH resolution. (A) SNP-only effect (the 
addition of an effect allele, coded as 1, increases NASH resolution. 
Treatment and placebo have approximately the same rate of 
increase in resolution). (B) SNP and treatment interaction effect 
(the addition of an effect allele increases NASH resolution, and 
this increase is further heightened by treatment group, as the OCA 
group increases at a much larger rate than the placebo group).
taBle 1. sentinel snps assoCiateD WitH 
nasH Resolution DemonstRating eFFeCt 
on pHenotype RegaRDless oF tReatment 
ReCeiVeD (snp-only eFFeCt), oR tHose 
inteRaCting WitH tReatment to aFFeCt 
tHe pHenotype (snp anD tReatment 
inteRaCtion eFFeCt)
SNP-Only Effect SNP and Treatment Interaction Effect
rs61811017 rs75508464
rs67955805 rs113171415
rs2971355 rs7677101
rs7712188 rs13148620
rs118086828 rs1859173
rs1866671 rs17133280
rs71550675 rs34105677
rs78542190 rs12593699
rs34668456 rs11649290
rs35787382 rs35871798
rs75520616 rs4969304
rs11216486 rs2202067
rs73112049 rs111832226
rs2959341
rs36111385
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near TDRD10 on chromosome 1 and rs4073431 near 
ANO3 on chromosome 11 were also associated with 
improvement in portal inflammation and steatosis, 
respectively. None of these sentinel SNPs was associ-
ated with ALT or development of pruritus.
genome-WiDe assoCiation 
analysis FoR pRuRitus
In the 197 white participants analyzed (106 on 
OCA, 91 on placebo), pruritus was commonly self- 
reported during the FLINT trial occurring in 25% 
of participants receiving OCA versus 4% of those 
receiving placebo. In the genome-wide association 
analysis to identify variants associated with pruri-
tus in the entire cohort (Fig. 5), we noted multiple 
SNPs on chromosome 11 with suggestive association 
with pruritus. The top sentinel SNP was rs1379650 
(P  = 2.1 × 10−6). ANO5 was as the nearest upstream 
gene to this SNP.
This SNP demonstrates a SNP and treatment inter-
action effect, and appears to augment the OCA effect 
on pruritus (odds ratio [OR] of entire cohort = 6.94, 
OR of OCA = 7.36) (Supporting Fig. S5).
We subsequently compared the SNPs associated 
with NASH resolution to those associated with 
pruritus in the OCA group (Supporting Fig. S6). 
We noted no overlap between these SNPs, sug-
gesting that if there is indeed genetic contribution 
to pruritus in this setting, the genetic mechanisms 
and regions contributing to development of pruritus 
on OCA are independent of those associated with 
NASH resolution.
Discussion
NAFLD is the most common liver disease in the 
United States.(20) Liver failure and liver cancer due to 
NASH are on the rise, with NASH currently being 
Fig. 3. Genotype bar plot for top SNPs from model 1. (*Excludes missing data; 0/0  =  homozygous reference; 0/1  =  heterozygous; 
1/1 = homozygous alternate; above each bar is the sample size for each group and relative frequency.)
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the second most common indication for liver trans-
plant listing in the United States.(21) Therefore, there 
is an urgent need to develop effective therapies to halt 
or reverse the progression of NASH and prevent its 
complications. This has translated into a remarkable 
increase in clinical trials to test the potential therapeu-
tic agents for NASH.(22) However, as seen in major 
randomized clinical trials for NASH, only a sub-
group of participants achieves the desired histological 
improvement. NASH resolution, when chosen as the 
primary endpoint, has been observed in 20%-47% of 
participants in different trials.(3,23,24) Understanding 
the host genetic factors that may influence response 
to a certain therapeutic agent may therefore allow a 
more effective and personalized delivery of therapy 
to patients with NASH who have a high chance of 
response. It may also spare patients with a low chance 
of response the exposure to a therapeutic agent that 
they may not respond to and also spare them the side 
effects of such agent.(25,26)
In this study, we identified several genetic vari-
ants associated with NASH resolution and fibrosis 
improvement in participants in the FLINT trial. To 
our knowledge, except for variants in MAPK10, which 
were previously reported to be associated with liver 
enzymes levels in another GWAS,(27) the other vari-
ants and nearby genes identified in this study had not 
been previously reported to be associated with NASH 
or with response of liver disease to therapeutic agents 
(Supporting Table S5).
Although five of the six sentinel SNPs associated 
with NASH resolution were also associated with 
improvement of one or two additional NAFLD his-
tological phenotypes, rs75508464 near CELA3B on 
chromosome 1 was notably associated with improve-
ment in NAS, fibrosis, and portal inflammation. The 
CELA3B encodes for elastase 3B, which is secreted 
from the pancreas and helps in digestion. The elastase 
3B isoform can be measured in stool as a measure of 
pancreatic exocrine function.(28) A variant in CELA3B 
has a possible protective effect on the risk of chronic 
alcoholic pancreatitis,(29) and hypermethylation of the 
gene promoter may be associated with pancreatic can-
cer.(30) However, no data are currently available on the 
role of CELAB3 in liver disease.
Similarly, while seven of the eight sentinel SNPs 
associated with fibrosis improvement were also nom-
inally associated with NASH resolution or improve-
ment, rs12130403 near TDRD10 on chromosome 1 t
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Fig. 4. Manhattan and Q-Q plots for fibrosis improvement in the entire cohort (A), in the OCA-treated group (B), and in the placebo-
treated group (C).
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and rs4073431 near ANO3 on chromosome 11 were 
also associated with improvement in portal inflamma-
tion and steatosis, respectively. Variants in TDRD10 
and ANO3 have been linked to neurological dis-
eases(31,32) but not yet to liver disease.
This study highlights the concept that host genetic 
variants may on their own affect the outcomes of 
intervention, positively or negatively, and regard-
less of treatment received (SNP-only effect) (e.g., 
rs118086828, FYN, and rs71550675, CREB3L2 in 
Fig. 3.). This could partly explain improvements seen 
in recipients of placebo. Indeed, 15 of the 28 sentinel 
SNPs associated with NASH resolution had a SNP-
only effect.
In some patients, certain genetic variants not 
only increased the likelihood of response but also 
enhanced the effect of treatment (SNP and treat-
ment effects). This is best highlighted in the 21 par-
ticipants who were heterozygotes for the rs75508464 
variant in CELA3B; these participants already had a 
higher NASH resolution rate compared with the null 
homozygotes and demonstrated further increase in 
response to OCA. As seen in Fig. 2B, 83% of those 
participants who received OCA achieved NASH 
resolution, compared with only 33% of those who 
received placebo.
Nearly a quarter of the participants in this analysis 
developed pruritus on OCA. We identified a sentinel 
SNP (rs1379650) near ANO5, which was associated 
with pruritus. ANO5 has been linked to thyroid can-
cer, gnathodiaphyseal dysplasia and myopathy,(33-35) 
but not yet to liver disease. This variant also shows 
a SNP and treatment effect and increased the likeli-
hood of pruritus in participants receiving OCA.
This pharmacogenomics study size was relatively 
small, but this was a consequence of the already estab-
lished size of the original FLINT trial. Because this 
is a unique population with NASH exposed to OCA, 
validation in another similar cohort was not feasible 
at the time. The upcoming phase 3 randomized trial 
of OCA in NASH (NCT02548351) may offer an 
opportunity to validate these findings. We restricted 
our GWAS to white participants, who represented 
most of the cohort, to avoid false positives introduced 
by population stratification. The results therefore may 
not be applicable to patients of other races. Due to 
the modest study size, the significance threshold for 
examining associations was set at 10−4, which is lower 
than the traditional 10−8 for GWAS. Despite these 
limitations, this study has several strengths. It eval-
uated a unique population with NASH that received 
either OCA or placebo. The histological phenotypes 
were blindly and systematically well-defined by the 
NASH CRN Pathology Committee. The observa-
tion that a number the genetic regions we identified 
had multiple associated SNPs, and that the sentinel 
SNPs in several of these regions were associated with 
improvement in multiple histological phenotypes, 
are also encouraging, and increase the likelihood of 
true significance and reduce the possibility of false 
discovery. Although these results could be viewed as 
tentative, they can trigger further research to confirm 
Fig. 5. Manhattan and Q-Q plots for pruritus.
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and explore the biological and clinical significance of 
identified sentinel SNPs.
In conclusion, we identified several genetic variants 
that may be associated with NASH resolution and 
fibrosis improvement in participants in the FLINT 
trial. The rs75508464 variant in CELA3B on chro-
mosome 1 may have a significant effect on the rate 
of NASH resolution in those who received OCA. 
If confirmed, these variants may improve the effec-
tiveness and precision of selecting NASH patients 
for OCA therapy by offering it to those with vari-
ants that increase the likelihood of NASH resolu-
tion. Once established, NASH patients with genetic 
variants associated with low likelihood of response to 
OCA and high likelihood of pruritus may be directed 
to receive different therapies.
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